Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Gilead's Earning

|Includes: Gilead Sciences, Inc. (GILD)

Gilead(NASDAQ:GILD) - I think the company will beat earning estimate by +.02 cents.

The R&D cost will be high due to phase III trial of HCV.

The guidance will beat analysts estimates.

Disclosure: I am long GILD.